PD-L1 expression in nonclear-cell renal cell carcinoma
Top Cited Papers
- 1 November 2014
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 25 (11), 2178-2184
- https://doi.org/10.1093/annonc/mdu445
Abstract
Programmed death ligand-1 (PD-L1) expression in nonclear-cell RCC (non-ccRCC) and its association with clinical outcomes are unknown. Formalin-fixed paraffin-embedded (FFPE) specimens were obtained from 101 patients with non-ccRCC. PD-L1 expression was evaluated by immunohistochemistry in both tumor cell membrane and tumor-infiltrating mononuclear cells (TIMC). PD-L1 tumor positivity was defined as ≥5% tumor cell membrane staining. For PD-L1 expression in TIMC, a combined score based on the extent of infiltrate and percentage of positive cells was used. Baseline clinico-pathological characteristics and outcome data [time to recurrence (TTR) and overall survival (OS)] were correlated with PD-L1 staining. Among 101 patients, 11 (10.9%) were considered PD-L1+ in tumor cells: 2/36 (5.6%) of chromophobe RCC, 5/50 (10%) of papillary RCC, 3/10 (30%) of Xp11.2 translocation RCC and 1/5 (20%) of collecting duct carcinoma. PD-L1 positivity (PD-L1+) in tumor cells was significantly associated with higher stage (P = 0.01) and grade (P = 0.03), as well as shorter OS (P < 0.001). On the other hand, PD-L1 positivity by TIMC was observed in 57 (56.4%) patients: 13/36 (36.1%) of chromophobe RCC, 30/50 (60%) of papillary RCC, 9/10 (90%) of Xp11.2 translocation RCC and 5/5 (100%) of collecting duct carcinoma. A trend toward shorter OS was observed in patients with PD-L1+ in TIMC (P = 0.08). PD-L1+ in both tumor cell membrane and TIMC cells were associated with shorter TTR (P = 0.02 and P = 0.03, respectively). In non-ccRCC, patients with PD-L1+ tumors appear to have worse clinical outcomes, although only PD-L1 positivity in tumor cells is associated with higher tumor stage and grade.Keywords
Funding Information
- DF/HCC Kidney Cancer (SPORE: P50 CA101942-01)
- Trust Family, the Loker Pinard and the Michael Brigham Funds
This publication has 28 references indexed in Scilit:
- The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic ParametersThe American Journal of Surgical Pathology, 2013
- Pazopanib versus Sunitinib in Metastatic Renal-Cell CarcinomaThe New England Journal of Medicine, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Transcription Factor E3 and Transcription Factor EB Renal Cell Carcinomas: Clinical Features, Biological Behavior and Prognostic FactorsJournal of Urology, 2011
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomaBlood, 2010
- Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC NetworkAnnals of Oncology, 2010
- T-cell Co-regulatory Molecule Expression in Renal Angiomyolipoma and Pulmonary LymphangioleiomyomatosisUrology, 2009
- Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and TherapyClinical Cancer Research, 2007
- Checkpoint Blockade in Cancer ImmunotherapyAdvances in Immunology, 2006
- Renal-Cell CarcinomaThe New England Journal of Medicine, 2005